SDIC, the largest state-owned investment holding company in China, led a $116m Series A round in Xuanzhu Biopharmaceutical, the innovative drug research and development platform of Sihuan Pharmaceutical. "Xuanzhu Biopharmaceutical is deploying research and development of market-leading innovative drug, and is rapidly promoting clinical research and development and marketing, thus building a strong platform. We are very happy to support Xuanzhu Biopharmaceutical's highly efficient team at this exciting stage. They are using their expertise and capabilities to expand treatment options and benefit Chinese patients," SDIC.